Cross-Sector entity
Every one of those 1 sits in a single category, fda-approval. CBER is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Bespoke Gene Therapy Consortium, all published on February 24, 2026.
1 verified story tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. CBER is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Bespoke Gene Therapy Consortium, all published on February 24, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bespoke Gene Therapy Consortium. Shared-story counts are live from our verified record — not editorial picks.
Formal Proposal
FDA formally proposes the new customized drug approval system for ultra-rare diseases.
BGTC Pilot Completion
The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
Draft Guidance Issued
FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
PREVENT Act Passed
Congress directs FDA to establish a framework for platform technology designations.
The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
